JP2016164177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016164177A5 JP2016164177A5 JP2016077977A JP2016077977A JP2016164177A5 JP 2016164177 A5 JP2016164177 A5 JP 2016164177A5 JP 2016077977 A JP2016077977 A JP 2016077977A JP 2016077977 A JP2016077977 A JP 2016077977A JP 2016164177 A5 JP2016164177 A5 JP 2016164177A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- group
- heterocyclyl
- alkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 59
- 125000003118 aryl group Chemical group 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 31
- -1 halomethyl ketone Chemical class 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000005382 boronyl group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 claims description 2
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 31
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 30
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 8
- 108050006947 CXC Chemokine Proteins 0.000 claims 7
- 102000019388 CXC chemokine Human genes 0.000 claims 7
- 229910019142 PO4 Inorganic materials 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 235000021317 phosphate Nutrition 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000019693 Lung disease Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 150000008065 acid anhydrides Chemical class 0.000 claims 5
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 5
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 239000002184 metal Substances 0.000 claims 5
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 5
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 5
- 102000019034 Chemokines Human genes 0.000 claims 4
- 108010012236 Chemokines Proteins 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical group NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 claims 4
- 150000007942 carboxylates Chemical class 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003862 glucocorticoid Substances 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 229940124761 MMP inhibitor Drugs 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 2
- 239000003172 expectorant agent Substances 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 238000012261 overproduction Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 claims 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 claims 1
- GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 229940122858 Elastase inhibitor Drugs 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- 229930194542 Keto Chemical group 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 102000048266 Nociceptin Human genes 0.000 claims 1
- 108090000622 Nociceptin Proteins 0.000 claims 1
- 108010014865 PLIalpha Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229940123898 Phospholipase A2 inhibitor Drugs 0.000 claims 1
- 229940117896 Phospholipase D inhibitor Drugs 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002597 adenosine A2 receptor agonist Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960003896 aminopterin Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000005513 benzoazaindolyl group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003602 elastase inhibitor Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229940042385 glatiramer Drugs 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 239000000536 muscarinic M2 receptor agonist Substances 0.000 claims 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 claims 1
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 claims 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37622410P | 2010-08-23 | 2010-08-23 | |
| US61/376,224 | 2010-08-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526073A Division JP6486002B2 (ja) | 2010-08-23 | 2011-08-22 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016164177A JP2016164177A (ja) | 2016-09-08 |
| JP2016164177A5 true JP2016164177A5 (enExample) | 2018-06-14 |
Family
ID=45594546
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526073A Active JP6486002B2 (ja) | 2010-08-23 | 2011-08-22 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
| JP2016077977A Withdrawn JP2016164177A (ja) | 2010-08-23 | 2016-04-08 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
| JP2018222400A Withdrawn JP2019069946A (ja) | 2010-08-23 | 2018-11-28 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526073A Active JP6486002B2 (ja) | 2010-08-23 | 2011-08-22 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018222400A Withdrawn JP2019069946A (ja) | 2010-08-23 | 2018-11-28 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8779149B2 (enExample) |
| EP (1) | EP2608672B1 (enExample) |
| JP (3) | JP6486002B2 (enExample) |
| AU (1) | AU2011293612B2 (enExample) |
| CA (1) | CA2811990C (enExample) |
| WO (1) | WO2012027289A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| CN110420316A (zh) | 2013-06-18 | 2019-11-08 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点 |
| US8969365B2 (en) * | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| EP3027627B1 (en) * | 2013-08-02 | 2018-01-31 | Syntrix Biosystems Inc. | 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| WO2017070589A1 (en) * | 2015-10-22 | 2017-04-27 | Duke University | Methods and compositions for the diagnosis and treatment of central nervous system autoimmune diseases |
| CN109152780B (zh) * | 2016-03-11 | 2021-10-01 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| US20190216790A1 (en) * | 2016-10-13 | 2019-07-18 | The Regents Of The University Of California | Methods for Treating Pruritis |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| WO2021163683A1 (en) | 2020-02-14 | 2021-08-19 | President And Fellows Of Harvard College | Inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof |
| CN121039109A (zh) | 2023-04-18 | 2025-11-28 | 国家科学研究中心 | 3,5-二氨基三唑衍生物及其用于治疗眼部疾病的用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE817911C (de) | 1947-12-16 | 1951-10-22 | Chem Fab Tempelhof Preuss & Te | Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden |
| US4139623A (en) | 1974-05-14 | 1979-02-13 | C-G Corp. | Cyclic-substituted derivatives of 1-amino-2-propanol |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US4973597A (en) | 1989-06-30 | 1990-11-27 | Eli Lilly And Company | Anticonvulsant agents |
| US5475120A (en) | 1990-11-02 | 1995-12-12 | University Of Florida | Method for the isolation and purification of taxol and its natural analogues |
| US5194635A (en) | 1991-03-18 | 1993-03-16 | Virginia Tech Intellectual Properties, Inc. | Rearranged taxol compounds and method of using in testing of in vivo activity |
| FR2684103B1 (fr) | 1991-11-22 | 1994-09-02 | Centre Nat Rech Scient | Nouveaux composes a structure guanidique et composition pharmaceutique les contenant. |
| US5488116A (en) | 1992-03-30 | 1996-01-30 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol and analogues thereof |
| US5416225A (en) | 1992-03-30 | 1995-05-16 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol |
| WO1993021173A1 (en) | 1992-04-17 | 1993-10-28 | Abbott Laboratories | Taxol derivatives |
| AU4220193A (en) * | 1992-04-29 | 1993-11-29 | Sri International | Deazaaminopterins for treatment of inflammation |
| US5461169A (en) | 1992-06-23 | 1995-10-24 | The Scripps Research Institute | Total synthesis of taxol and taxol analogs |
| US5440057A (en) | 1993-08-20 | 1995-08-08 | The Scripps Research Institute | Access to taxol analogs |
| WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
| US5478854A (en) | 1992-10-01 | 1995-12-26 | Bristol-Myers Squibb Company | Deoxy taxols |
| US5411984A (en) | 1992-10-16 | 1995-05-02 | Virginia Tech Intellectual Properties, Inc. | Water soluble analogs and prodrugs of taxol |
| CA2126698A1 (en) | 1992-12-07 | 1994-06-23 | Muraleedharan G. Nair | Process for the isolation and purification of taxol and taxanes from taxus spp. |
| US5468769A (en) | 1993-07-15 | 1995-11-21 | Abbott Laboratories | Paclitaxel derivatives |
| FR2707642B1 (fr) | 1993-07-16 | 1995-10-13 | Electricite De France | Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques. |
| US5405972A (en) | 1993-07-20 | 1995-04-11 | Florida State University | Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes |
| US5565478A (en) | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| GB9405347D0 (en) | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| US5508447A (en) | 1994-05-24 | 1996-04-16 | Board Of Regents, The University Of Texas System | Short synthetic route to taxol and taxol derivatives |
| US5489589A (en) | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6506747B1 (en) * | 1998-06-05 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| JP2003520854A (ja) | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
| HUP0302415A2 (hu) | 2000-05-19 | 2003-11-28 | Merck Patent Gmbh | Triazolszármazékokat tartalmazó gyógyszerkészítmények és új triazolszármazékok |
| WO2002053544A1 (en) | 2000-12-29 | 2002-07-11 | Darwin Discovery Ltd. | Pharmaceutical uses and synthesis of nicotinanilide-n-oxides |
| CZ20032829A3 (cs) | 2001-04-16 | 2005-03-16 | Tanabe Seiyaku Co., Ltd. | Heterocyklické sloučeniny |
| CN1242910C (zh) * | 2001-06-29 | 2006-02-22 | 三菱电机株式会社 | 电梯卷扬机及电梯装置 |
| US6777432B1 (en) * | 2001-09-04 | 2004-08-17 | Darwin Molecular Corporation | Pharmaceutical uses and synthesis of nicotinamides |
| CA2465978C (en) * | 2001-09-14 | 2015-04-07 | Soon Hyung Woo | Inhibitors of histone deacetylase |
| US6521395B1 (en) | 2002-01-30 | 2003-02-18 | Eastman Kodak Company | Infrared couplers for incorporating and recovering metadata |
| US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| AU2003255819A1 (en) * | 2002-08-24 | 2004-03-11 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
| US20040116479A1 (en) * | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| TW200505450A (en) | 2003-02-03 | 2005-02-16 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| US7459460B2 (en) * | 2003-05-28 | 2008-12-02 | Bristol-Myers Squibb Company | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
| CA2576971A1 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| WO2006028958A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| US7091202B2 (en) * | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| JP2006117568A (ja) | 2004-10-20 | 2006-05-11 | Mitsubishi Pharma Corp | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 |
| WO2006070806A1 (ja) | 2004-12-28 | 2006-07-06 | Taiho Pharmaceutical Co., Ltd. | 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物 |
| US20060276515A1 (en) | 2005-05-06 | 2006-12-07 | Cywin Charles L | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same |
| WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| WO2007008963A1 (en) | 2005-07-13 | 2007-01-18 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
| PT1924560E (pt) | 2005-09-01 | 2009-10-23 | Lilly Co Eli | 2,3,4,5-tetra-hidro-1h-benzo[d]azepinas como agonistas de receptores 5-ht2c |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| BRPI0620066A2 (pt) * | 2005-12-20 | 2011-11-01 | Novartis Ag | derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados |
| WO2007098352A2 (en) | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| JP2009544611A (ja) | 2006-07-20 | 2009-12-17 | メルク エンド カムパニー インコーポレーテッド | ヒストン脱アセチル化酵素阻害剤としてのリン誘導体 |
| MX2009003981A (es) | 2006-10-26 | 2009-04-27 | Amgen Inc | Agentes moduladores del receptor de calcio. |
| SG173409A1 (en) * | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| WO2008073461A2 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
| EP2097379A1 (en) * | 2006-12-11 | 2009-09-09 | Wyeth a Corporation of the State of Delaware | Carboxamide derivatives as ion channel modulators |
| WO2008123469A1 (ja) * | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | ６員環アミド化合物およびその用途 |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US8263585B2 (en) * | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
| CN101765425A (zh) * | 2007-08-02 | 2010-06-30 | 弗·哈夫曼-拉罗切有限公司 | 苯甲酰胺衍生物用于治疗cns障碍的用途 |
| CA2695331A1 (en) | 2007-08-03 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| JP5587193B2 (ja) | 2007-10-23 | 2014-09-10 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なキナーゼ阻害剤 |
| JP5301557B2 (ja) * | 2007-12-04 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| US20110124626A1 (en) * | 2008-07-18 | 2011-05-26 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives and their use as histamine h3 antagonists |
| BRPI0918045A2 (pt) | 2008-09-18 | 2015-12-01 | Astellas Pharma Inc | compostos de carboxamida heterocíclicos |
| EP2942346B1 (en) * | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| EP2236505A1 (de) * | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
| KR101354416B1 (ko) * | 2009-05-07 | 2014-02-19 | 에프. 호프만-라 로슈 아게 | 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체 |
| BR112012004149A2 (pt) * | 2009-08-25 | 2016-03-22 | Abraxis Bioscience Llc | terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
-
2011
- 2011-08-22 AU AU2011293612A patent/AU2011293612B2/en active Active
- 2011-08-22 JP JP2013526073A patent/JP6486002B2/ja active Active
- 2011-08-22 US US13/215,014 patent/US8779149B2/en not_active Ceased
- 2011-08-22 EP EP11820471.8A patent/EP2608672B1/en active Active
- 2011-08-22 CA CA2811990A patent/CA2811990C/en active Active
- 2011-08-22 WO PCT/US2011/048668 patent/WO2012027289A1/en not_active Ceased
-
2014
- 2014-05-20 US US14/283,118 patent/US8993541B2/en not_active Ceased
-
2016
- 2016-04-08 JP JP2016077977A patent/JP2016164177A/ja not_active Withdrawn
- 2016-07-14 US US15/210,803 patent/USRE47740E1/en active Active
-
2017
- 2017-03-24 US US15/469,395 patent/USRE48547E1/en active Active
-
2018
- 2018-11-28 JP JP2018222400A patent/JP2019069946A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100496493C (zh) | 2-氨基-4,5-三取代噻唑基衍生物 | |
| ES2317889T3 (es) | Derivados de tiazolilo 2,4-disustituido. | |
| JP6486002B2 (ja) | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド | |
| TWI395749B (zh) | 吡咯并〔１，２-ｂ〕嗒酮化合物 | |
| JP2017533968A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| JP2005533005A5 (enExample) | ||
| CA2479126A1 (en) | Combination treatments for chemokine-mediated diseases | |
| JP2008509137A5 (enExample) | ||
| JP2006206609A5 (enExample) | ||
| JP2008503585A5 (enExample) | ||
| JP2007520440A5 (enExample) | ||
| JPH05503919A (ja) | 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制 | |
| JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
| JP2012519691A5 (enExample) | ||
| JP2007509114A5 (enExample) | ||
| JP2004529874A5 (enExample) | ||
| JP2017519781A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2010528009A5 (enExample) | ||
| JP2012006982A (ja) | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト | |
| JP2011506412A5 (enExample) | ||
| WO1998029397A1 (en) | Fused pyrimidine compounds and medicinal use thereof |